Abivax Announces Full Year 2025 Financial Results and Provides Business UpdatesABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trial The Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026 Abivax appointed Michael Nesrallah, MBA as Chief Commercial Officer, bringing extensive IBD leadership experience to support the Company’s next phase of growth; other key senior leadership hires made in Regulatory Affairs and Research to support continued advancements of its programs Cash, cash equivalents and short-term investments of €530.4M...

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity program, including POWER and STRENGTH trials, on voluntary pause pending next steps with ARD-101; further guidance on the program expected in Q2 2026 Clinical and preclinical data from ARD-101 program published in Molecular Metabolism  $110.0 million in cash, cash equivalents and short-term investments as of December 31, 2025, supports projected operations into the second quarter of 2027 SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways...

Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, PhD, president and CEO of Bionano. “Our routine users of optical genome mapping (OGM) and VIA™ software remain the foundation of our revenue and gross margins, and we are pleased to see continued growth in utilization among this core customer base. The global OGM community continues to show extraordinary energy, from the record attendance and engagement at the Bionano Symposium 2026 – where leading laboratories described scaling OGM workflows to potentially thousands of samples per year – to the continued expansion...

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program targeting PTK7, STRO-227, accelerating IND submission to 2026 – – Astellas-partnered iADC dual-payload program enters the clinic; patient dosing underway – – Cash, cash equivalents and marketable securities as of December 31, 2025 of $141.4 million, excluding proceeds from the recent capital raise of approximately $110 million which extended cash runway into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),...

Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced financial results for the fourth quarter and full year 2025 and provided a business update. Business...

TORONTO, March 23, 2026 (GLOBE NEWSWIRE) — Quadravest Preferred Split Share ETF (“Preferred ETF”) announces that its annual financial statements and management report of fund performance for the year ended December 31, 2025 are now available at www.sedarplus.com and Preferred ETF’s website at www.quadravest.com. For further information, please contact Investor Relations at 416-304-4443, toll free at 1-877-4-Quadra (1-877-478-2372), or visit www.quadravest.com.

Export expansion and improved margins underpin sustained performance SINGAPORE, March 23, 2026 (GLOBE NEWSWIRE) — HomesToLife Ltd (Nasdaq: HTLM) (“HomesToLife” or the “Company”), a Singapore-based home furniture company with sales across Asia-Pacific, Europe and North America, today announced its audited financial results for the fiscal year ended December 31, 2025 (“FY2025”). “We are pleased to deliver strong operational and financial results for the full year, underpinned by our diversified export model and disciplined capital management,” said Ms. Phua Mei Ming, Chief Executive Officer of HomesToLife. “As we move forward, we will continue to execute our expansion strategy, deepen our presence in key markets, and ensure that HomesToLife remains well positioned to capture new growth opportunities.”Key Financial Highlights    FY2024     FY2025     Chg...

TAKHMAO, Cambodia, March 23, 2026 (GLOBE NEWSWIRE) — Kandal M Venture Limited (Nasdaq: FMFC) (“Kandal” or the “Company”), a contract manufacturer of affordable luxury leather goods with manufacturing operations in Cambodia, today announced its financial results for its first half of fiscal year 2026 ended September 30, 2025. Recent DevelopmentsStrategic Expansion into the PhilippinesOn March 9, 2026, the Company announced a strategic investment to expand its manufacturing capabilities into the Philippines-its first major expansion outside Cambodia. Kandal entered into a definitive agreement to acquire 15% equity interest in Dumaine International Ltd for US$2.5 million in an all-cash transaction. This investment supports the Company’s long-term strategy to diversify geographically, broaden its customer base, and enhance operational...

VANCOUVER, British Columbia, March 23, 2026 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”, “we” or “us”) (TSX: CFF) today reported results for the fourth quarter and year ended December 31, 2025. EBITDA* from continuing operations was negative $12.6 million for the quarter and negative $27.5 million for the year, compared to EBITDA of negative $2.1 million in the fourth quarter of 2024 and negative $13.6 million for the year. Net loss was $35.7 million or negative $0.87 per share for the year versus net loss in the preceding year of $29.8 million or $0.73 per share.  Selected Financial Highlights The following table summarizes our selected financial information for the comparative periods. Unless otherwise noted, financial information reflects results of continuing operations from our Mackenzie sawmill (the “Mackenzie...

BEIJING, March 23, 2026 (GLOBE NEWSWIRE) — Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today announced its financial results for the fiscal year ended December 31, 2025. The Company’s Annual Report on Form 20-F was filed with the U.S. Securities and Exchange Commission on March 20, 2026. Management Commentary “We are pleased to report another year of solid financial performance, driven by continued momentum across our CHEERS ecosystem,” said Mr. Bing Zhang, Chairman and Chief Executive Officer of Cheer Holding. “Revenue growth was supported by new customer contributions, while we continued to advance our strategic focus on artificial intelligence and have begun laying the groundwork...